In Silico Technologies in Drug Target Identification and Validation

Darryl Leon, Scott Markel

June 13, 2006 by CRC Press
Reference - 504 Pages - 9 Color & 72 B/W Illustrations
ISBN 9781574444780 - CAT# DK3273
Series: Drug Discovery Series

USD$209.95

Add to Wish List
FREE Standard Shipping!

Features

  • Presents the most recent trends based on significant advances made in genomics, proteomics, and bioinformatics since the 1970s
  • Examines genomic correlations between different organisms and various models that simulate disease progression in humans
  • Details the components of BioIT hardware configuration and architecture requirements, a key tool for supporting in silico research
  • Reviews the numerous tools, initiatives, projects, and standards for ontologies and how they can be used in the drug discovery process
  • Provides examples and tables to illustrate the use of a particular technology as well as recommended books, journal articles, and Web sites for further information
  • Summary

    The pharmaceutical industry relies on numerous well-designed experiments involving high-throughput techniques and in silico approaches to analyze potential drug targets. These in silico methods are often predictive, yielding faster and less expensive analyses than traditional in vivo or in vitro procedures.

    In Silico Technologies in Drug Target Identification and Validation addresses the challenge of testing a growing number of new potential targets and reviews currently available in silico approaches for identifying and validating these targets. The book emphasizes computational tools, public and commercial databases, mathematical methods, and software for interpreting complex experimental data. The book describes how these tools are used to visualize a target structure, identify binding sites, and predict behavior. World-renowned researchers cover many topics not typically found in most informatics books, including functional annotation, siRNA design, pathways, text mining, ontologies, systems biology, database management, data pipelining, and pharmacogenomics.

    Covering issues that range from prescreening target selection to genetic modeling and valuable data integration, In Silico Technologies in Drug Target Identification and Validation is a self-contained and practical guide to the various computational tools that can accelerate the identification and validation stages of drug target discovery and determine the biological functionality of potential targets more effectively.

    Daniel E. Levy, editor of the Drug Discovery Series, is the founder of DEL BioPharma, a consulting service for drug discovery programs. He also maintains a blog that explores organic chemistry.